Anson Funds Management’s bluebird bio BLUE Stock Holding History

Anson Funds Management’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,752	Closed	-$350K	–	352
2021 Q4	$350K	Buy	+1,752	New	+$413K	0.03%	268

Other funds holding BLUE

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Anson Funds Management's BLUE Position: Q1 2022 in Review

Anson Funds Management sold out of bluebird bio (BLUE) in Q1 2022, closing a stake of 1,752 shares — an estimated $350K sold.

Anson Funds Management first reported a position in BLUE in Q4 2021 and held it in 1 quarter. The position peaked at $350K in Q4 2021. 174 funds tracked by Wall St. Rank hold BLUE as of Q1 2022.

Anson Funds Management reported no remaining bluebird bio position as of Q1 2022 after selling out during the quarter.
Anson Funds Management sold 1,752 bluebird bio shares in Q1 2022, an estimated $350K.
Anson Funds Management first reported a position in bluebird bio in Q4 2021 and held it in 1 quarter.
Anson Funds Management's bluebird bio position peaked at $350K in Q4 2021.
174 funds tracked by Wall St. Rank held bluebird bio as of Q1 2022.

Based on Anson Funds Management's 13F filing for Q1 2022, filed 12 May 2022.